Alignment Healthcare Faces Hagens Berman Probe After 16.7% Stock Plunge
ALHC•Hagens Berman has launched an investigation into Alignment Healthcare after whistleblower allegations that the company misclassified operating expenses as capital expenditures to inflate EBITDA. The disclosure triggered a 16.7% one-day stock decline, marking ALHC’s worst session since February 2024.
1. Probe Initiation
Hagens Berman filed an investor alert stating that whistleblowers allege Alignment Healthcare shifted routine operating expenses into capital expenditures to boost EBITDA and other financial metrics. The probe seeks to determine the extent of any accounting irregularities and whether investors were misled.
2. Market Reaction
Following the allegations, Alignment Healthcare’s shares tumbled 16.7% in a single session, representing its steepest daily drop since February 2024. Trading volume spiked as investors assessed the potential fallout from the investigation.
3. Potential Implications
If the probe substantiates the misclassification claims, Alignment Healthcare could face restatements, regulatory fines and shareholder lawsuits. The company’s credibility with Medicare Advantage partners and future capital-raising efforts may also be at risk.
